Introduction
The mycotoxin and food contaminant ochratoxin A (OTA) is one of the most potent renal carcinogens studied to date. In a 2 year carcinogenicity bioassay in F344 rats, relatively low doses of OTA (70 and 210 lg/kg body wt) were shown to induce high incidences of adenomas and carcinomas (1, 2) . Moreover, tumors induced by OTA were characterized by an unusual, aggressive phenotype and high potential to metastasize (1, 2) . The molecular events leading to renal tumor formation by OTA and the reason for the aggressive nature of OTA-induced tumors are still poorly understood. While direct genotoxicity via formation of covalent DNA adducts does not appear to play a role (3) (4) (5) (6) , there is evidence to suggest that OTA may promote genomic instability and tumorigenesis through interference with cell division. In several mammalian cell lines and primary cells, OTA was shown to inhibit cell cycle progression by arresting cells at G 2 /M phase (7) (8) (9) and to increase micronucleus formation, whereby both aneugenic and clastogenic effects were observed (10) (11) (12) (13) . Recent cytogenetic analyses revealed a significant increase in endoreduplicated cells, indicating two successive rounds of DNA replication without intervening mitosis (14) . In immortalized human kidney epithelial cells, OTA blocked metaphaseanaphase transition and led to the formation of aberrant metaphases with misaligned chromosomes and giant cells with abnormally enlarged and/or multiple nuclei, which sometimes remained connected by chromatin bridges (15) . Although immunostaining of the mitotic apparatus revealed defects in spindle formation in the form of asymmetric and sometimes multipolar mitotic spindles, OTA did not inhibit microtubule assembly in a cell-free polymerization assay at relevant concentrations (15) , suggesting that OTA may disrupt mitosis through mechanisms other than direct binding to tubulin.
In vivo, early effects of OTA at doses known to cause renal tumor formation after long-term treatment (70 and 210 lg/kg body wt) consist of cell loss accompanied by prominent nuclear enlargement and a doseand time-related increase in 5-bromo-2-deoxyuridine (BrdU) labeling within the straight segment of the proximal tubule epithelium (P3) in the outer stripe of the outer medulla, from which OTA-induced tumors arise (16, 17) . While it is well established that regenerative cell proliferation in response to cytotoxicity is an important feature of many non-genotoxic carcinogens in the kidney (18) , OTA-induced kidney pathology appears to be significantly different from that induced by other renal carcinogens operating through a non-genotoxic/cytotoxic mode of action, in that simple tubule hyperplasia, which frequently occurs as a result of compensatory cell proliferation, does not occur in response to OTA treatment, whereas the frequency and early onset of karyomegaly appear to be unique to OTA. Disruption of cell division, leading to the production of polyploid nuclei instead of simple tubule hyperplasia, may provide a potential explanation for the apparent disparity between kidney pathology induced by OTA compared with other renal carcinogens, and it appears likely that blocked mitosis may even represent the principal cause of cell degeneration and subsequent trigger for cell proliferation to compensate for the presumed deficit in daughter cells. These findings are consistent with the mitotic aberrations observed in immortalized human kidney epithelial cells treated with OTA in vitro and support the hypothesis that it is the failure of cells to complete mitosis in the presence of OTA that causes both cell death and nuclear abnormalities (15) .
A growing body of evidence indicates that aberrant cell division, aneuploidy and cancer may occur as a result of misregulation of mitosis-related genes, which govern faithful replication and segregation of chromosomes. For instance, untimely inactivation of cyclindependent kinase 1 (Cdk1 cdc2 ) during mitosis has been shown to cause premature exit from mitosis without nuclear division and cytokinesis (mitotic slippage), leading to polyploidy and nuclear aberrations (19) similar to those observed in OTA-treated immortalized human kidney epithelial cells. Likewise, Polo-like kinase 1 (Plk1), which is known to be involved in spindle assembly, centrosome maturation and separation, chromosome segregation and cytokinesis, has been shown to exihibit oncogenic potential, and overexpression of Plk1 has been associated with multinucleation, chromosomal instability (CIN), aneuploidy and poor prognosis in tumor patients (20) . Depletion of Plk1 by small interfering RNA has been shown to reduce cell survival in human cancer cells and inhibit colony formation in soft agar and tumor growth in mice, demonstrating that Plk1 acts as an oncogene (21) (22) (23) . Aurora B, a serine/threonine kinase and part of the chromosomal passenger complex with distinct functions in chromosome condensation, segregation and cytokinesis through regulation of microtubule kinetochore associations, is frequently overexpressed in various tumors, including renal cell carcinomas, and often correlates with poor prognosis and high metastatic potential (20, (24) (25) (26) (27) . Experimental evidence for a role of Aurora B in malignant transformation has also come from studies demonstrating Aurora B upregulation in early foci of estrogeninduced Syrian hamster kidney tumors, suggesting that elevated expression of Aurora kinases leading to centrosome amplification, chromosomal instability and aneuploidy may drive estrogen-mediated oncogenesis (28) , as well as from studies showing chromosome number instability in Chinese hamster embryo cells in response to forced overexpression of Aurora B (29) .
Considering the close link between mitotic defects and genetic instability, the nuclear aberrations observed in response to OTA treatment and the malignant phenotype of OTA-induced tumors in rats, we speculated that the mechanism of OTA carcinogenicity may involve altered function of key regulators of mitosis, resulting in blocked or asymmetric cell division, accompanied by an increased risk of aneuploidy acquisition and subsequent tumor formation. To gain further insight into the early molecular changes involved in OTA carcinogenicity, we used quantitative real-time (qRT) polymerase chain reaction (PCR) arrays, which combine the quantitative performance of qRT-PCR with the multiple gene profiling capabilities of microarrays, supported by immunohistochemistry and immunoblotting, to analyze the time-and dose-related expression of a focused panel of genes critically involved in cell cycle control and progression through mitosis in kidneys of male F344 rats treated with OTA at doses of 0, 21, 70 and 210 lg/kg body wt for up to 90 days. The arrays were specifically designed to cover genes involved in all stages of the cell cycle (G 1 /S, G 2 and M phase) and included cyclin-dependent kinases, cyclins, cyclin-dependent kinase inhibitors, a range of oncogenes and tumor suppressor genes that control cell proliferation and cell survival, genes related to the DNA damage and spindle assembly checkpoints, as well as genes encoding for growth factors and growth factor receptors.
Materials and methods
Reagents OTA was purchased from Axxora (Grünberg, Germany). Primary antibodies used were rabbit anti-GAPDH (Sigma-Aldrich, Deisenhofen, Germany), mouse anti-Cdk1 cdc2 (17; Santa Cruz Biotechnology, Heidelberg, Germany), mouse anti-p21 (clone SMX30; BD Biosciences PharMingen, Heidelberg, Germany), rabbit anti-p-histone H3 (Ser10; Santa Cruz Biotechnology), goat anti-cyclin A (D-19; Santa Cruz Biotechnology), rabbit anti-cyclin B1 (Acris Antibodies GmbH, Hiddenhausen, Germany), rabbit anti-cyclin E1 (AbD Serotec, Düsseldorf, Germany), goat and mouse Plk (N-19 and F-8; Santa Cruz Biotechnology), mouse anti-Plk1 (clone 35-206; Abcam, Cambridge, UK), rabbit anti-Plk1 pT210 (Rockland Immunochemicals, Gilbertsville, PA), rabbit anti-Aurora B (Abcam and Cell Signaling Technology, Beverly, MA), rabbit anti-survivin (Novus Biologicals, Littleton, CO), rabbit anti-topoisomerase II alpha (Epitomics, Burlingame, CA), rabbit anti-separase (Abcam) and mouse anti-BubR1 (clone 9; BD Transduction Laboratories, Lexington, KY). Secondary antibodies were obtained from Santa Cruz Biotechnology and streptavidinhorseradish peroxidase and 3,3#-diaminobenzidine substrate kit were purchased from BD Biosciences PharMingen.
Tissue samples
Tissue samples were obtained from a 90 day oral gavage study in which male F344 rats were treated with OTA dissolved in corn oil at doses of 0, 21, 70 and 210 lg/kg body wt for 14 and 90 days, 5 days/week as described previously (16) . The study was conducted in accordance with guidelines for the humane treatment of animals after approval by the appropriate authorities. At necropsy, kidneys and livers were removed, aliquoted and flash frozen in liquid nitrogen and stored at À80°C until analysis. For immunohistochemical studies, aliquots of kidney and liver were fixed in 10% neutral buffered formalin and embedded in paraffin.
RNA isolation
RNA was extracted from kidney and liver tissue using Total RNA Isolation Reagent (Abgene, Hamburg, Germany), followed by DNA digestion and further purification using RNeasy Mini Kit (Qiagen, Hildesheim, Germany) according to the manufacturer's instructions. RNA was quantified by measuring the absorbance at 260 nm. RNA integrity was determined by 1.2% agarose gel electrophoresis. Purified RNA samples were stored at À80°C until use.
Complementary DNA synthesis and expression profiling Complementary DNA was synthesized from 1 lg total RNA by using RT 2 PCR array first strand kit (SA Bioscience, Frederick, MD) according to the manufacturer's protocol. Samples were quality controlled using RT 2 RNA QC PCR arrays (SA Bioscience) and subsequently used as template for qRT-PCR using custom made RT 2 Profiler PCR arrays (SA Bioscience 40 cycles of 95°C for 15 s and 60°C for 1 min. Specificity of PCR products was examined by melting curve analysis. Amplification efficiency between samples was estimated using standard curves. The C t values were normalized to five housekeeping genes (Rplp1, ribosomal protein, large, P1; Hprt, hypoxanthine guanine phosphoribosyl transferase; Rpl13a, ribosomal protein L13A; Ldha, lactate dehydrogenase A and Actb, b-Actin) and changes in gene expression relative to controls were calculated using the DDC t method. Data are expressed as mean fold change relative to control animals (n 5 3). Statistical analysis was performed by analysis of variance and Dunnett's post hoc test. Statistically significant changes are indicated as Ã P , 0.05, ÃÃ P , 0.01 and ÃÃÃ P , 0.001. A 2-fold change in expression level or a P-value ,0.05 were considered as biologically significant. A heat map visualizing relative expression of all genes on the array was generated using the Cluster and TreeView software (30) , and principal component analysis was performed using SIMCA-P version 11.5 (Umetrics, Umea, Sweden).
Immunohistochemistry
Immunohistochemical studies were performed on 5 lm sections of paraffinembedded kidneys. Sections were deparaffinized, hydrated and washed in phosphate-buffered saline (PBS) or PBS containing 0.1% Tween-20. Antigen retrieval was performed by heating for 4 min in citrate buffer (pH 6.0 and pH 4.0) using a pressure cooker. Endogenous peroxidase was blocked by 3% H 2 O 2 in PBS for 15 min. Subsequently, sections were washed in PBS and blocked with normal serum (10% in PBS) for 1.5 h, followed by incubation with avidin and biotin solution (0.001% in PBS) for 15 min, with several wash steps in between. Then, slides were incubated with primary antibody in 1% bovine serum albumin in PBS overnight at 4°C in a humidified chamber. Dilutions of antibodies were as follows: anti-Cdk1 cdc2 and anti-p21, 1:50; anti-topoisomerase II alpha, 1:200; anti-p-histone H3 (Ser10), 1:100; anti-survivin, 1:200 and anti-Plk1, anti-Aurora B and anti-separase from 1:50 to 1:500. After washing with PBS or PBS containing 0.1% Tween-20, the sections were incubated for 1.5 h at room temperature with biotinylated secondary antibody and were subsequently washed three times. Following incubation with streptavidin-horseradish peroxidase for 30 min, immunoreactivity was visualized using 3,3#-diaminobenzidine for 1-3 min (BD Biosciences PharMingen). The sections were counterstained with hematoxylin, dehydrated and finally mounted in Eukitt mounting medium (SigmaAldrich). Images were acquired at Â200 magnification using an Olympus CH-2 microscope fitted with an Olympus E330 digital camera.
Western blot
Kidneys were homogenized in RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 2 mM ethylenediaminetetraacetic acid, 1% Nonidet P40 and 0.1% sodium dodecyl sulfate), supplemented with 1 mM NaF, 1 mM Na 3 VO 4 and protease inhibitor cocktail (Sigma) and centrifuged at 8000g for 15 min at 4°C. The protein concentration of the lysate was determined using the DC Assay method (Bio-Rad, Munich, Germany). Aliquots of 20-50 lg protein in Laemmli buffer (Sigma) were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto nitrocellulose membranes at 100 V for 75 min at 4°C using transfer buffer (25 mM Tris, 192 mM glycine and 20% methanol). Membranes were blocked in 5% non-fat dry milk in TBST buffer (50 mM Tris-HCl, 150 mM NaCl and 0.1% Tween-20, pH 7.4) for 2 h at room temperature following incubation with primary antibodies diluted in blocking buffer overnight at 4°C [anti-cyclin B1, 1:500; anti-cyclin A, 1:1000; anti-Plk1 (F-8, 1:200; N-19, 1:1000; pT210, 1:1000); anti-Aurora B, 1:200; anti-cyclin E1, 1:2000; anti-GAPDH, 1:20 000 and anti-BubR1, 1:500]. After several washing with TBST, horseradish peroxidase-conjugated antibodies were incubated at a dilution of 1:5000 in blocking buffer for 1 h at room temperature and detection of proteins was performed using ECL detection system (GE Healthcare, Munich, Germany). Densitometric analysis was performed using the Bio-Rad Gel Doc 2000 system (Bio-Rad, Munich, Germany).
Results
Time-and dose-dependent effects on gene expression profiles Oral administration of OTA at doses known to cause renal tumor formation after chronic treatment resulted in significant time-and dose-related changes in the expression of genes of interest in kidneys of male F344 rats (Figures 1 and 2) . Of the 84 genes on the array, 20 genes were significantly upregulated after treatment with 70 and 210 lg OTA/kg body wt for 90 days as compared to controls, whereas only two genes were downregulated in kidneys of high-dose animals (Figure 2) . In contrast, no alterations in gene expression were evident in kidneys of rats treated with a low dose of OTA (21 lg/kg body wt) or in the liver (210 lg/kg body wt), which is not a target for OTA carcinogenicity (Figures 1 and 2 ). To identify early molecular changes involved in the mechanism of OTA carcinogenicity, gene expression profiles were also investigated in kidneys of rats after a 14 day treatment with OTA at doses of 0, 21, 70 and 210 lg/kg body wt, which caused minor histopathological changes in high-dose animals, consisting of lining cell degeneration in the form of condensed cells with dense eosinophilic cytoplasm and contracted nuclei and nuclear variability implying a slight increase in nuclear size scattered through affected tubules (16) . The majority of genes (16/22) affected by a 90 day OTA treatment were also found to be deregulated after 2 weeks administration of 210 lg OTA/kg body wt, albeit to a lesser extent (Figure 2 ). In contrast, treatment with 70 lg/kg body wt for 2 weeks did not induce significant changes in messenger RNA (mRNA) expression levels, consistent with the absence of histopathological changes at this dose/time point. Genes significantly altered in response to OTA treatment are summarized in Table I . Quantitative data obtained from all genes on the array are provided as supplement (supplementary Table 1 is available at Carcinogenesis Online).
Genes significantly deregulated by treatment with OTA for 14 days Early effects of OTA in rat kidney included changes in the expression of positive regulators of cell cycle kinases, such as the G 1 /S-specific cyclin E1, the S phase/mitotic cyclins A2, B1 and B2 and c-myc (Table I) . In contrast, expression of D-type cyclins (D1 and D2), which is highly growth factor dependent and drives cell cycle progression through G 1 phase in response to extracellular signals, remained unchanged (supplementary Table 1 is available at Carcinogenesis Online). mRNA levels of cyclin H, the regulatory subunit of Cdk7, a cyclin-dependent kinase-activating kinase and cyclin G 1 , a target of p53, were also not affected by OTA treatment.
In contrast to cyclin-dependent kinases active during G 1 /S phase (i.e. Cdk 2, 4 and 6), Cdk1 cdc2 , which associates with A-and B-type cyclins and plays a key role during mitosis, was found to be upregulated $3-fold in response to OTA treatment. Likewise, Plk1, which mediates phosphorylation of cyclin B1 and Cdc25C leading to activation of Cdk1 cdc2 -cyclin B1 in addition to its role in chromosome condensation and separation, was induced in kidneys of OTA-treated rats as compared to controls. At the same time, OTA treatment resulted in a significant increase in the expression of negative regulators of cell cycle progression, i.e. p21 WAF1/CIP1 and 14-3-3sigma, but not p53 and Gadd45 (Table I and supplementary Table 1 is available at Carcinogenesis Online).
Aurora kinase B and survivin, both members of the chromosomal passenger complex required for mitotic checkpoint function, as well as the mitotic checkpoint genes Bub1b and Cdc20 were significantly upregulated in kidneys of OTA-treated animals. In addition, OTA induced the expression of Espl1 (separase), which cleaves sister chromatid cohesion at the onset of anaphase, along with its inhibitor Pttg1 (securin) and topoisomerase II alpha, involved in mitotic chromosome segregation after DNA replication. indicating genes that were downregulated. A similar expression pattern was observed in kidneys of mid-(70 lg/kg body wt) and high-dose (210 lg/kg body wt) rats after 90 days treatment, and in high-dose animals after 14 days, although effects were less pronounced at this early time-point. In contrast, no significant alterations in gene expression profiles were evident in kidneys of rats treated with a low dose (21 lg/kg body wt) for up to 90 days or in the liver after high-dose treatment.
Early events in OTA carcinogenicity
Genes significantly deregulated by treatment with OTA for 90 days qRT-PCR analysis following 90 days treatment revealed more pronounced increases in the expression of those genes found to be deregulated after 14 days. The most upregulated gene was the Cdk inhibitor p21 WAF1/CIP1 , which was increased .11-fold after 90 days, whereas other Cdk inhibitors, such as p16 Ink4a , p57 Kip2 or p27 Kip1 , were not modulated by OTA (Table I and supplementary Table 1 is available at Carcinogenesis Online). The mitotic protein kinases Aurora B, Plk1, Cdk1 cdc2 , Bub1b and several cyclins (A2, B1, B2, E1) were upregulated .5-fold in kidneys of high-dose animals relative to controls.
In addition to the gene expression changes observed after 14 days treatment, continuous administration of OTA (70 and 210 lg/kg body wt) for 90 days resulted in a significant increase in mRNA levels of c-fos, cyclin E2 and checkpoint kinase 1 (Chek1), which plays a role in recognition of DNA damage and replication defects to preserve genomic integrity.
In contrast to the marked upregulation of most cell cycle and mitosis-related genes, a highly significant decrease in the expression of regucalcin (.15-fold) was observed after treatment with 210 lg/kg body wt OTA for 90 days, in line with a recent microarray study (31) . At the same time, Ca (2+) /calmodulin (CaM)-dependent protein kinase, which is involved not only in calcium signaling but also in initiation of centrosome duplication, was significantly increased in response to OTA. The only other gene found to be downregulated in response to OTA was the gene encoding for the gap junction membrane channel protein beta 1 (connexin 32), a tumor suppressor gene involved in gap junction intercellular communication-mediated growth control.
Interestingly, no changes in the expression of a range of growth factors (epidermal growth factor, insulin-like growth factor 1, platelet-derived growth factor and transforming growth factor beta 1) or their receptors were detected in kidneys of rats treated with OTA (supplementary Table 1 is available at Carcinogenesis Online), suggesting that mitogenic signaling via overexpression of growth factors/growth factor receptors may not play a major role in OTA-mediated stimulation of renal cell proliferation.
Immunohistochemical and western blot analyses
In good agreement with changes in gene expression, immunohistochemical anaylsis revealed time-and dose-dependent alterations in protein expression in proximal tubule epithelial cells located in the outer stripe of the outer medulla, from which tumors in OTA-treated rats arise. Enhanced expression of Cdk1 cdc2 , the key regulator of mitosis, was detected in affected tubules in kidneys of OTA-treated animals. Diffuse cellular staining consistent with its role in G 2 /M phase was evident in high-dose animals after 14 days treatment and in kidneys of animals exposed to 70 and 210 lg/kg body wt OTA for 90 days ( Figure 3A) , whereas Cdk1 cdc2 protein was not detected in control or low-dose animals. Western blotting did not reveal significant changes in the expression of cyclins A and B, which were not detectable by immunohistochemistry (Figure 4) .
However, a striking increase in p21 WAF1/CIP1 protein was detected in epithelial cells within the outer stripe of the outer medulla and medullary rays as early as 14 days after treatment with 210 lg/kg body wt OTA, and in mid-and high-dose animals after 90 days. Kidneys of control and low-dose animals showed no immunoreactivity toward p21 WAF1/CIP1 . p21 WAF1/CIP1 immunostaining revealed nuclear localization, predominantly in cells with enlarged nuclei, consistent with its role in maintaining G 1 arrest after aberrant exit from mitosis ( Figure 3B ). In addition, degenerate cells frequently exhibited enhanced p21 WAF1/CIP1 immunoreactivity ( Figure 3B ), suggesting that p21 WAF1/CIP1 may contribute to mitotic failure via untimely inactivation of Cdk1 cdc2 .
An occasional cell positively stained for topoisomerase II was noted in proximal tubule cells of control animals ( Figure 3C ). However, the number of cells showing topoisomerase II immunoreactivity was significantly increased in kidney sections of high-dose animals after 14 days and in mid-and high-dose rats exposed for 90 days ( Figure 3C ). Topoisomerase II staining localized to the nucleus, whereby cells with increased nuclear content were frequently positive for topoisomerase II.
In contrast to rat thymus extract (Santa Cruz Biotechnology), K-ras-transformed normal rat kidney cell lysate (Santa Cruz Biotechnology) and HeLa cells that were used as positive controls, Aurora B, separase, BubR1 and Plk1 were not detectable in rat kidney by either immunohistochemistry or immunoblotting even after nuclear enrichment using a range of antibodies (data not shown), presumably due to the low level of expression as suggested by reports demonstrating the presence of these proteins in tumors but not in surrounding normal tissues (32) (33) (34) (35) . However, increased phosphorylation of histone H3 on Ser10 indicative of enhanced Aurora B activity was evident in OTAtreated animals. Interestingly, phospho-H3 (Ser10) was evident in abnormally enlarged mitotic figures but also in pyknotic nuclei of degenerate cells detached from the basal membrane, which may indicate that cell death in these cells may have occurred during mitosis ( Figure 3D) .
Consistent with gene expression data, overexpression of survivin, a member of the inhibitor of apoptosis family and chromosomal passenger complex, was detected in renal tubule cells of OTA-exposed rats by immunohistochemical analysis. Enhanced expression of Images were acquired at Â200 magnification using an Olympus CH-2 microscope fitted with an Olympus E330 digital camera.
Early events in OTA carcinogenicity survivin was evident in cells with enlarged nuclei, suggesting that survivin may contribute to the survival of these genetically unstable, polyploid cells ( Figure 3E ).
Discussion
We have shown previously that single-cell degeneration, compensatory DNA replication and marked nuclear enlargement indicative of blocked nuclear division during mitosis and subsequent inhibition of cytokinesis are prominent features of OTA nephrotoxicity under conditions of carcinogenicity (16) . Based on these findings, we hypothesized that OTA may interfere with signaling pathways controlling entry into the cell cycle and coordinate progression through mitosis, thereby causing mitotic aberrations, proliferation and consequently malignant transformation. In this study, we used low-density real-time PCR arrays, which allow a more accurate analysis of low-abundance mRNAs than GeneChip microarrays due to their much wider dynamic range, to investigate changes in the expression of a focused panel of genes selected based on their known function in cell proliferation and growth control. Our results show that the early histopathological changes induced by OTA in rat kidney are associated with significant alterations in the expression of several key regulators of mitosis, including molecules involved in centrosome function, G 2 /M progression, chromosome condensation and segregation, spindle checkpoint and cytokinesis, whereas genes implicated in G 1 progression, G 1 -S transition or growth factor signaling were generally not modulated by exposure to OTA ( Figure 5) . No changes were seen in the liver as a non-target organ. Immunohistochemical analysis confirmed upregulation of mitosis-control proteins in S3 proximal tubule cells, which represent the target cells of OTA carcinogenicity, presumably due to preferential uptake and intracellular accumulation of OTA at this site (36, 37) .
In recent years, it has become increasingly more evident that genetic and epigenetic alterations in mitotic genes that coordinate equal distribution of the genetic material between two daughter cells may be associated with tumor development and act as a driving force during malignant progression. Evidence for this has come from numerous reports demonstrating overexpression of mitosis-related genes in a wide variety of human cancers, as well as from experiments using genetically engineered mice and cultured cells (38) . Moreover, loss of mitotic regulation leading to chromosomal instability and alterations in chromosome number (aneuploidy) frequently correlates with tumor malignancy and poor prognosis. Carter et al. (39) recently identified a signature of 70 genes associated with chromosomal instability, overexpression of which predicted clinical outcome in patients. Among these genes, 29 play key roles in mitosis (38) . Importantly, this gene signature contains several genes that we found to be significantly upregulated in kidneys of OTA-treated animals as early as after 14 days treatment, including Aurora kinase B, Cdk1 cdc2 , Cdc20, cyclin B1, cyclin B2, Espl1 (separase) and Pttg1 (securin), providing strong evidence for mitotic deregulation and chromosome instability as an early and perhaps initiating event in tumor formation by OTA. Furthermore, the close link between tumor malignancy and aberrant expression of genes associated with chromosomal instability may help explain why OTA-induced kidney tumors develop with such a rapid onset and are characterized by aggressive growth, tendency toward an uncommon anaplastic phenotype and high potential to metastasize (1, 18) .
In our study, we also observed differential expression of a number of genes that are not part of Carter's chromosomal instability signature but are also intimately linked to mitosis and growth control and, indeed, tumor development. These include A-and E-type cyclins, myc, the mitotic spindle checkpoint gene Bub1b (encoding BubR1), the mitotic protein kinase Plk1, survivin, p21 WAF1/CIP1 and the gene encoding the gap junction membrane channel protein beta 1 (Cx32). Although the precise mechanism of how gap junction proteins regulate growth control still remains to be elucidated, there is a wealth of evidence which shows that connexins function as tumor suppressors and that sustained inhibition of gap junction intercellular communication provides a tumor-promoting stimulus (40) . In renal cell carcinomas from hemodialysis patients, Cx32 is transcriptionally inactivated (41) , and transfection of Cx32 into metastatic renal cell carcinoma cells lacking endogenous Cx32 suppresses growth, invasion and metastasis of renal tumor cells (42, 43) . The downregulation of Cx32 mRNA observed in this study is in line with previous reports which demonstrate that disruption of gap junction intercellular communication may play a role in the mechanism of tumor formation by OTA (44, 45) . However, the fact that significant alterations were evident in high-dose animals only after 90 days treatment indicates that loss of Cx-mediated growth control may well be a contributing, but not primary, event in OTA carcinogenicity. Similarly, expression of regucalcin (also known as senescence marker protein 30), which decreases with aging and has been shown to play a cytoprotective role against intracellular calcium elevation and oxidative stress (46) , was only affected following 90 days treatment with the high dose of OTA.
In contrast, several cancer-related genes that function as oncogenes were significantly upregulated as early as after 14 days OTA treatment. Overexpression of E-and A-type cyclins, which may be mediated by myc, is not only associated with proliferation but is also considered to be linked to malignant phenotype and chromosomal instability (47) . In late G 1 and during S phase, cyclins E and A sequentially activate Cdk2, which has been proposed to act as a key regulator in the initiation of centrosome duplication (48) . Centrosome duplication, separation and function are essential for formation of bipolar mitotic spindles and accurate chromosome segregation. Consequently, numeral and functional abnormalities of centrosomes may result in mitotic aberrations and are thought to be a major cause of genomic instability. Besides E-and A-type cyclins, a large number of cancer-associated genes are known to be involved in the regulation of centrosome number, including myc, CaMKII, Chek1 and Plk1, which were also found to be deregulated in kidneys of OTA-treated rats. In addition to regulating centrosome duplication and function, Plk1 plays multiple roles during mitosis, including chromosome condensation and separation (20, 49) . Plk1 cooperates with Aurora B and separase (both associated with CIN and also overexpressed in response to OTA) in mediating removal of cohesin, which maintains sister chromatid cohesion, leading to separation of sister chromatids (50, 51) . Interestingly, Mosesso et al. (14) recently showed that OTA induces aberrant condensation and separation of chromatids, which may be mediated in part by Plk1, Aurora B and separase. In addition, overexpression and Plk1-dependent phosphorylation of topoisomerase II alpha (upregulated 2.6-and 6.2-fold after 14 and 90 days OTA treatment, respectively), which plays crucial roles in mitotic chromosome assembly and organization, may contribute to premature chromosome condensation (52) , whereas increased expression of BubR1 (Bub1b), a spindle checkpoint protein that senses lack of attachment and tension at kinetochores, may block mitotic progression through inhibition of the anaphase promoting complex APC/C Cdc20 (53) . Both BubR1 (Bub1b) and topoisomerase II alpha are frequently elevated in Early events in OTA carcinogenicity various cancers and high expression levels of topoisomerase II alpha have been linked with poor differentiation and aggressive tumor phenotype (54) (55) (56) (57) (58) (59) .
Although most of the genes differentially expressed in kidneys of OTA-treated rats are cell cycle related, it needs to be emphasized that upregulation of mitotic genes linked to chromosomal instability is not considered to be simply a reflection of cell proliferation (38, 39) . This is also supported by the fact that significant increases in gene expression, but not BrdU labeling (16) were evident in kidneys of rats following 14 days treatment with OTA. At this time point, single proximal tubule cell death was an important feature of OTA nephrotoxicity, and the finding that degenerate cells were frequently positive for phospho-H3 (Ser10) indicates that cell death is likely to have occurred during mitosis. Commitment to apoptosis in response to mitotic disruption might be seen as a protective means to prevent generation of genetically unstable polyploid cells and subsequent oncogenesis. After 90 days, however, cell degeneration was less frequent, but the incidence and degree of karyomegaly was increased as compared to earlier time points, along with a significant increase in BrdU-labeled cells (16) . This suggests that the deficit in daughter cells being formed may provide a strong and continuous stimulus for cells to become resistant against apoptosis, thereby causing a shift toward mitotic exit, cell proliferation and reentry of tetraploid cells into a second round of DNA synthesis. It is possible that the overexpression of Birc5 (survivin) observed in this study may contribute to cell survival following continuous exposure to OTA. Survivin, a chromosomal passenger protein and member of the inhibitor of apoptosis gene family, is upregulated in various tumors, and it has been speculated that tumor cells may exploit the antiapoptotic function of survivin to evade apoptosis (60) . Survivin function is regulated at the transcriptional and post-transcriptional level and requires sharp cell cycle-dependent transcription at mitosis and post-transcriptional modification, including phosphorylation by Cdk1 cdc2 and Aurora B. On the other hand, there is also evidence that survivin gene transcription may be driven by non-cycle-dependent signaling pathways, including Wingless (Wnt)/T cell factor (TFC)-b-catenin, AKT and nuclear factor-jB signaling, and, indeed, results from a number of in vitro or in vivo studies suggest that OTA may modulate these pathways (15, 31, 45, 61, 62) .
In our study, p21 WAF1/CIP1 , which is commonly considered to possess tumor suppressor function, was significantly upregulated in kidneys of OTA-treated rats, particularly in cells with giant nuclei. It is thought that post-mitotic G 1 arrest in response to spindle damage and aberrant exit from mitosis is dependent on p21 WAF1/CIP1 and serves to prevent tetraploid cells from re-entering the cell cycle (63) . However, there is accumulating evidence that p21 WAF1/CIP1 may inhibit apoptosis through interfering with stress-signaling pathways (c-Jun N-terminal kinase and p38) and binding to pro-caspase-3, thereby preventing its activation (64) . Thus, overexpression of p21 WAF1/CIP1 in tetraploid/ polyploid cells may block secondary apoptosis after mitotic slippage and promote the survival of cells with nuclear aberrations. This suggests that aberrant expression of p21 WAF1/CIP1 may indeed contribute to genomic instability and tumor formation (19, 65) . In addition, we found p21 WAF1/CIP1 was not only expressed in polyploidy cells but also in degenerate cells. Chang et al. (19) have shown that inactivation of the Cdk1 cdc2 -cyclin B1 complex through transient overexpression of p21 WAF1/CIP1 during mitosis may cause transcriptional inhibition and rapid loss of mitosis-control proteins, leading to growth arrest, and abnormal mitosis and endoreduplication in recovering cells.
In tumor therapy, DNA endoreduplication and polyploidization in response to chemotherapeutic agents have been suggested to be a means of tumor cells to escape cell death. Importantly, however, it has been shown that these cells, which can survive for weeks, can resume proliferation and play an important role in tumor relapse (66) . Thus, the potential of polyploid cells to survive for prolonged periods of time and re-enter the cell cycle, thereby increasing the risk of aneuploidy acquisition, may not only be a key event in the mechanism of OTA carcinogenicity but may also have important implications for the time of exposure required to induce tumor formation by OTA. In view of human risk assessment of OTA in food, it is also important to emphasize that the dose-response of the transcriptional changes after 90 days is in perfect agreement with the dose-response for nephrotoxicity, BrdU labeling and, indeed, tumor formation after chronic treatment. Thus, the absence of changes at the low dose of 21 lg/kg body wt, which did not result in increased BrdU labeling (16) or tumor incidence (1), confirms the non-linearity of the dose-response and provides further support for a thresholded mechanism of OTA carcinogenicity.
In summary, the finding that OTA specifically modulates key regulators of chromosome segregation and progression through mitosis even after short-term treatment provides crucial evidence in support of a mechanism of OTA carcinogenicity involving disruption of mitosis and chromosomal instability ( Figure 5) . Although the precise mechanism as to how OTA functions to perturb the intricate and tightly controlled process of mitosis remains to be elucidated, it is well established that interference with the mitotic machinery and subsequent chromosome segregation errors leading to numerical or structural chromosomal aberrations can introduce multiple genetic alterations simultaneously and act as a driving force in tumorigenesis and acquisition of a malignant phenotype.
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